Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$13B
P/E ratio
29×
Div yield
0%
EPS (2025)
$15.28
Profit margin
18%
Rev. growth
+20%
Revenue
$2.5B
Backlog
$3.0B
In plain English
Medpace is a full-service clinical contract research organization (CRO) — the outsourced R&D engine that runs Phase I-IV drug trials for small and mid-sized biotech. It never owns a drug; sponsors pay it to design, staff and manage trials across ~5,900 people in 44 countries. Founder-CEO August Troendle still controls ~20%, and its disciplined, single-operating-model approach converts ~18% of $2.5B revenue to net income.
In simple terms
Where Medpace sits
Medpace is the outsourced R&D middle of the drug chain: biotech sponsors hand it a drug candidate, and it runs the Phase I-IV trials — organizing investigator sites, its own central labs, and regulatory submissions — so the sponsor can (if the data works) win approval and sell the medicine.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.